TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00923130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
Study: NCT01402609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic discharge communication tool
Description: The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
Study: NCT04257825

Intervention type: DEVICE
Group type: OTHER
Intervention: Chili Sleep System
Description: A mattress pad that cools or warms bed to maintain a constant temperature.

Intervention type: DEVICE
Group type: OTHER
Intervention: Chili Sleep System
Description: A mattress pad that cools or warms bed to maintain a constant temperature.
Study: NCT03124771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow Resposable Adhesive Sensors
Description: Noninvasive Measurement of SpHb
Study: NCT04632758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: tablets, 60 mg→180mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crizotinib
Description: Capsules, 250mg, BID
Study: NCT00684255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Allogeneic Transplant
Description: Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Allogeneic Transplant
Description: Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg Days _8, -7, -6, -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg Days _8, -7, -6, -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
Study: NCT03847129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based tendon gliding and resistance training
Description: The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
Study: NCT03782376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab approximately 6 mg/kg (IV)
Description: Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SC)
Description: Participants will receive SC injection of placebo at Week 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (IV)
Description: Participants will receive IV infusion of placebo at Week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (SC) Group 1
Description: Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 90 mg (SC) Group 2
Description: Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
Study: NCT02714920

Intervention type: OTHER
Group type: OTHER
Intervention: CHEMRAD assay
Description: CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
Study: NCT02124564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day.
Study: NCT01651715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAO1, oral homeopathic antibodies
Description: TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAO1, oral homeopathic antibodies
Description: TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).
Study: NCT03715894

Intervention type: PROCEDURE
Intervention: transcatheter valve implantation
Description: aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
Study: NCT00074321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01245504

Intervention type: OTHER
Intervention: Assessed for socket fit
Description: Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
Study: NCT04694664

Intervention type: OTHER
Intervention: This is an online survey with no intervention.
Description: As this is an online survey about health and wellbeing, there is no intervention.

Intervention type: OTHER
Intervention: This is an online survey with no intervention.
Description: As this is an online survey about health and wellbeing, there is no intervention.
Study: NCT01483742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg orally bid, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg orally bid, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg orally bid, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200 mg/kg/day orally in two divided doses, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200 mg/kg/day orally in two divided doses, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg orally bid, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg orally bid, 24 weeks
Study: NCT01015651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
Study: NCT04224675

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
Study: NCT04264403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation
Description: The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
Study: NCT03739905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier (BBB) Disruption
Description: Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
Study: NCT04518462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL (bupivacaine liposome injectable suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL (bupivacaine liposome injectable suspension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.25% bupivacaine
Study: NCT04763642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
Study: NCT02136030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 4mg/kg/day, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B-deoxycholate
Description: 1mg/kg/day, IV infusion
Study: NCT01141842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exhalation analysis of breath sample
Description: breath sample is presented to sniffer dog in test tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exhalation analysis of breath sample
Description: breath sample is presented to sniffer dog in test tube

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: exhalation analysis of breath sample
Description: breath sample is presented to sniffer dog in test tube
Study: NCT01430455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
Study: NCT02292030

Intervention type: DRUG
Intervention: HTEA
Description: usually high thoracic epidural anesthesia

Intervention type: DRUG
Intervention: HTEA
Description: usually high thoracic epidural anesthesia
Study: NCT03077685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Study: NCT01933633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00476411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine
Description: HBV vaccine 3 doses at month 0, 1, and 6
Study: NCT03587220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical
Description: Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical
Description: Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet-B (UVB) irradiation
Description: Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine 1%
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
Study: NCT01222455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, single dose
Study: NCT05224999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 3mg/kg (every 2 weeks)
Study: NCT02182752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine - Tramadol
Description: Interscalene block using ropivacaine plus tramadol
Study: NCT01222455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, single dose
Study: NCT03180099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0.1 Bupivacaine administered to Epidural Space
Study: NCT04278339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evoked Related Potentials
Description: Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evoked Related Potentials
Description: Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
Study: NCT01660360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanibirumab
Study: NCT01076049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC)
Description: The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrisept Delivery System
Description: Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression.~Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits.
Study: NCT01217671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kamada AAT for inhalation
Description: Alpha-1 Antitrypsin (AAT)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02569814

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine/Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine/Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study: NCT02072408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: 1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~   * Loss of five ETDRS letters or one Snellen line of vision from baseline~  * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~  * Presence of active polyp on indocyanine green angiography
Study: NCT01088776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 Fatty Acid supplement
Description: Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
Study: NCT02450175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: 10 mg of Everolimus daily (by mouth)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: 2.5mg taken daily (by mouth)
Study: NCT03554876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Im Machined transepithelial component.
Description: Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Im Nanogolden transepithelial component
Description: Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Im Ti-Golden transepithelial component
Description: Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.